polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate
Drug data last refreshed 6h ago · AI intelligence enriched 9h ago
PLENVU is an oral polyethylene glycol (PEG)-based bowel prep solution indicated for colonoscopy preparation. It combines PEG 3350 with electrolytes (sodium sulfate, sodium chloride, potassium chloride) and vitamin C derivatives to cleanse the colon while minimizing fluid and electrolyte shifts. The formulation works as an osmotic laxative that draws water into the bowel to facilitate complete evacuation.
Product is in peak revenue phase with nearly 58K annual claims, indicating strong market penetration in the bowel prep category with mature commercial infrastructure.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu
A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy
A Pharmacokinetic Study of PLENVU® in Healthy Subjects
Worked on PLENVU at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PLENVU roles focus on commercial execution and market penetration in gastroenterology, with emphasis on physician relationships and patient adherence programs. Career growth is steady in a mature market with limited expansion opportunities outside core bowel prep indication.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo